Fluidigm Announces Second Quarter 2021 Financial Results with Total Revenue of $31.0 Million
August 05, 2021 16:05 ET
|
Fluidigm Corporation
Base business rebounds. Promising early reception to 4th generation mass cytometry instrument. Services business achieves quarterly revenue record of $6.6 million. SOUTH SAN FRANCISCO, Calif., Aug. ...
Fluidigm Announces Conference Call and Webcast of Second Quarter 2021 Financial Results
July 08, 2021 16:01 ET
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., July 08, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Fluidigm Announces First Quarter 2021 Financial Results with Total Revenue of $32.8 Million, Up 19 Percent Over Prior Year Period
May 06, 2021 16:05 ET
|
Fluidigm Corporation
Forecasting underlying base business growth of 16–17% supported by new product innovation SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an...
Inotiv, Inc. Enhances Histopathology Offering with Announcement of Agreement to Purchase HistoTox Labs, Inc.
April 13, 2021 16:35 ET
|
Inotiv, Inc.
WEST LAFAYETTE, Ind., April 13, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading provider of nonclinical and analytical contract research...
Psychedelic Partnership Reached, Ehave Inc. and Brain Scientific Sign Memorandum of Understanding to Map Brain Response to Psychedelic Treatment, Collaborate in the Development of Neural Net Algorithms for the Psychedelic Mental Health Sector, E-Tattoo Technology is Expected to Provide Continuous Monitoring
February 17, 2021 08:30 ET
|
Ehave
Ehave, Inc. to leverage data and AI to correlate biomarkers for the identification of psychedelic drug administration as a treatment for Chronic pain, Depression (major and persistent), PTSD, Bipolar...
Cognition Therapeutics Publishes Biomarker Findings from Clinical Study of CT1812 Supporting Positive Impact on Synapse Biology
February 10, 2021 08:00 ET
|
Cognition Therapeutics, Inc.
Pittsburgh, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular...
Inotiv Broadens Pathology Service Offerings
January 19, 2021 08:33 ET
|
Bioanalytical Systems, Inc.
WEST LAFAYETTE, Ind., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (“BASi”, the “Company”, “We”, “Our” or “Inotiv”), doing business as Inotiv, a leading provider of...
Fluidigm Announces Conference Call and Webcast of Fourth Quarter and Full Year 2020 Financial Results
January 07, 2021 16:02 ET
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Biomarkers Market Size Worth $115.45 Billion By 2027 | CAGR of 13.6%: Reports And Data
December 11, 2020 11:21 ET
|
Reports and Data
New York, Dec. 11, 2020 (GLOBE NEWSWIRE) -- The market growth is driven by technological advancements in post-genomic technologies and extensive applications of diagnostic biomarkers in precision...
Cognition Therapeutics Announces First Patient Dosed in SEQUEL Study of CT1812
August 27, 2020 07:59 ET
|
Cognition Therapeutics, Inc.
Pittsburgh, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular...